Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer

摘要: Prostate cancer is the most common non-cutaneous malignancy in American men. Standard therapeutic strategies for systemic disease include androgen-deprivation therapy (ADT) and chemotherapy, both of which are palliative. However, there a growing interest use immunotherapy prostate cancer. Evidence suggests that ADT may 1) enhance lymphopoiesis thus potentially improve immune responses to vaccine, 2) renew thymopoiesis reverse age-induced thymic involution, 3) augment B-cell development, 4) mitigate tolerance antigens. Although no vaccines currently approved cancer, many promising agents under investigation. This review focuses on recent findings regulation by androgens immune-system regeneration with ADT, emphasis rationale combination clinical treatment